Insider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sells 15,000 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 15,000 shares of the firm’s stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $17.22, for a total transaction of $258,300.00. Following the transaction, the chief accounting officer now directly owns 54,927 shares in the company, valued at approximately $945,842.94. This represents a 21.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Sandra Calvin also recently made the following trade(s):

• On Monday, November 25th, Sandra Calvin sold 12,090 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.30, for a total value of $221,247.00.

Travere Therapeutics Trading Down 2.8 %

Travere Therapeutics stock traded down $0.50 during trading hours on Friday, hitting $17.28. The stock had a trading volume of 669,097 shares, compared to its average volume of 1,387,978. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of -3.80 and a beta of 0.69. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The business’s 50 day simple moving average is $18.11 and its 200-day simple moving average is $13.35. Travere Therapeutics, Inc. has a one year low of $5.12 and a one year high of $20.33.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.01. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The business had revenue of $62.90 million during the quarter, compared to analyst estimates of $60.87 million. During the same quarter last year, the business earned ($1.17) EPS. The firm’s quarterly revenue was up 69.6% on a year-over-year basis. On average, equities analysts predict that Travere Therapeutics, Inc. will post -3.94 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TVTX has been the subject of several recent analyst reports. JPMorgan Chase & Co. upped their price objective on shares of Travere Therapeutics from $20.00 to $23.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. HC Wainwright lowered their price objective on shares of Travere Therapeutics from $23.00 to $18.00 and set a “buy” rating for the company in a research report on Friday, September 27th. Canaccord Genuity Group decreased their price target on Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a research note on Monday, September 30th. Wedbush upped their price objective on Travere Therapeutics from $17.00 to $25.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 9th. Finally, Wells Fargo & Company upgraded Travere Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $9.00 to $27.00 in a research report on Monday, October 21st. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $23.67.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds have recently modified their holdings of TVTX. Millennium Management LLC increased its holdings in Travere Therapeutics by 33.9% in the second quarter. Millennium Management LLC now owns 2,949,335 shares of the company’s stock valued at $24,244,000 after purchasing an additional 747,406 shares during the period. Emerald Advisers LLC grew its position in shares of Travere Therapeutics by 19.8% in the 3rd quarter. Emerald Advisers LLC now owns 1,960,659 shares of the company’s stock valued at $27,430,000 after buying an additional 323,513 shares during the last quarter. Finepoint Capital LP increased its stake in shares of Travere Therapeutics by 0.3% in the third quarter. Finepoint Capital LP now owns 1,782,267 shares of the company’s stock valued at $24,934,000 after buying an additional 5,539 shares during the period. Geode Capital Management LLC increased its stake in shares of Travere Therapeutics by 3.9% in the third quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company’s stock valued at $24,222,000 after buying an additional 64,744 shares during the period. Finally, Emerald Mutual Fund Advisers Trust raised its position in shares of Travere Therapeutics by 26.0% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 1,185,709 shares of the company’s stock worth $16,588,000 after acquiring an additional 244,444 shares during the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.